CRANBURY, N.J., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that an oral presentation and 3 posters related to its investigational pharmacological chaperones will be included at two upcoming scientific meetings.
October 30-November 4, 2012 in San Diego, CA
Long Term Effects of Migalastat HCl on Fabry Nephropathy. - Germain D.P., Giugliani R., Pastores G., Nicholls K., Shankar S., Schiffmann R., Hughes D., Mehta A., Waldek S., Jovanovic A., Bragat A., Sitaraman S., Sniukiene V., Winkler R., Boudes P.
November 6-10, 2012 in San Francisco, CA
Long-Term Safety of Migalastat HCl in Patients with Fabry Disease. – Germain D.P., Giugliani R., Pastores G., Nicholls K., Shankar S., Schiffmann R., Hughes D., Mehta A., Waldek S., Jovanovic A., Benistan K., Simosky J., Sniukiene V., Winkler R., Boudes P.
A Phase 2a Study to Investigate the Effects of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Alpha-Gal A Activity in Subjects with Fabry Disease. – Johnson F., Mudd Jr. P., Sitaraman S., Winkler R., Flanagan J., Khanna R., Valenzano K., Lockhart D., Boudes P. On Behalf of Study AT1001-013 Principal Investigators
High Incidence of GLA Variants in a Non-Selected Heart Disease Patient Population Suggests that the Fabry Trait is a Common Cardiovascular Genetic Risk Factor. - Schiffmann R., Forni S., Swift C., Wu X.,Lockhart D., Chee M., Kitaoka T., Chudin E., Pond S., McNeill N., Sims K., Benjamin E., Sweetman L.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.
Investors/Media: Sara Pellegrino firstname.lastname@example.org (609) 662-5044